access to medicines | 1 access to antimalaria medicines: the impact malaria approach f. bompart, m...
TRANSCRIPT
ACCESS TO MEDICINES | 1
Access to Antimalaria Medicines:the Impact Malaria approach
F. Bompart, M Bernhardt
ICIUM 2011, Antalya, November 16, 2011
Session 4f. Malaria : the role of medicines outlets in improving access to medicines
ACCESS TO MEDICINES | 2
Access to Medicines’ Mission & Objectives
●Mission● In emerging and developing countries, to improve access to
medicines for all patients, in particular the poorest, for selected diseases in which the Group has developed an expertise
● Two objectives● Corporate Social Responsibility: help break “disease-poverty” cycle● Economic: develop Sanofi’s presence in emerging and developing
countries
ACCESS TO MEDICINES | 3
Four Strategic Levers
●In partnership with external stakeholders, we mobilize Sanofi’s core skills to sustainably improve access to medicines by
1. Developing medicines to meet current and future patient needs
2. Making medicines affordable, through tiered-pricing
3. Providing information and educational tools for malaria
management
ACCESS TO MEDICINES | 4
The Impact Malaria The Impact Malaria programprogram
ACCESS TO MEDICINES | 5
15-25 kg
>35 kg
25-35 kg
5-15 kg
AM PM
Artemisinin-based combinations in 2004
Adult (>35 kg)
Child (17-35 kg)
Toddler(8-17 kg)
Infant(<8 kg)
Artesunate-AmodiaquineCo-blister
Arthemeter Lumefantrine
ACCESS TO MEDICINES | 6
15-25 kg
>35 kg
25-35 kg
5-15 kg
AM PM
Artemisinin-based combinations since 2007
Adult (>35 kg)
Child (17-35 kg)
Toddler(8-17 kg)
Infant(<8 kg)
Artesunate-AmodiaquineCo-blister
Arthemeter Lumefantrine“ASAQ”
ACCESS TO MEDICINES | 7
Malaria - Industrial
●Production of ASAQ in Morocco● WHO-certified GMP production● Production capacity increased to more than 70 million
treatments/year: 15 -20% of plant activity
ACCESS TO MEDICINES | 8
Public marketsArtesunate-Amodiaquine Winthrop® 25 blisters / boxPreferential price, including “no profit-no loss” prices < $1 for adults, <$0.50 for children
Private markets Coarsucam®
1 blister / box $2-3 wholesalers price
Affordable Medicines : Tiered-pricing policy
ACCESS TO MEDICINES | 9
Information and Educational tools
● Drugs alone are not enough
● Tools to promote comprehensive disease management● Prevention● Diagnosis● Treatment
● “Tool Box” to be adapted by local stakeholders
ACCESS TO MEDICINES | 10
Communities and families
> Health posts
> National hospitals
> Dispensaries
Primary care centers
> District hospitals
> Regional hospitals
Physicians-GPs
Nurses
Healthcare technicians
Tools for comprehensive management of malaria
ACCESS TO MEDICINES | 11
Côte d’Ivoire
ACCESS TO MEDICINES | 12
Burkina Faso
ACCESS TO MEDICINES | 13
« Schoolchildren against malaria »
1. Information on malaria to teachers
2. Schoolchildren informed on malaria
3. Schoolchildren design a theatre play
4. Contest between schools for best play
●Côte d’ivoire (3 sessions), Ghana (2), Burkina Faso (2)
● End 2010: > 200 000 children involved
ACCESS TO MEDICINES | 14
ASAQ Winthrop® - Delivery status
Global FundGlobal Fund
Global Fund, World Bank and/or PMI
Direct country purchase
ASAQ used in 21 countries
2008: 6 million treatments
2009: 25 million treatments
2010: 44 million treatments
July 2011: cumulative sales > 100 million
ACCESS TO MEDICINES | 15
Partnerships for Partnerships for Access to MedicinesAccess to Medicines
ACCESS TO MEDICINES | 16
Partnerships
● Access to medicines and to health: a complex set of issues● Political commitment● Budgets● Human resources● Heath infrastructures● Social security, insurance● Access to commodities, including medicines
• Affordable• Adapted• Accessible• Quality
● The pharmaceutical industry is only one of many stakeholders, based on its● Areas of expertise● Areas of legitimacy
ACCESS TO MEDICINES | 17
●Operating model based on partnerships
●Test new business models for the “base of the pyramid” patients● Access to medicines● Integrated disease management: prevention, diagnosis and
treatment.
Access to Medicines: a source of innovation
ACCESS TO MEDICINES | 18